BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a general company update at the CITI 2013 Global Healthcare Conference on Wednesday, February 27, 2013, at 3:00 p.m. ET. This conference will be held at the Hilton New York Hotel in New York City.
A live audio webcast of the presentation will be available at:
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817
CONTACT: Amarin contact information: Stephen Schultz or Joseph Bruno Amarin Corporation In U.S.: +1 (908) 719-1315 email@example.com